Seeing the effects of facial aging, including a loss of facial volume? Visible signs of aging in the face can be the result of several factors. While age factors like time are not within your control, others are. Sunscreen is an essential preventative measure for defending against volume loss, sagging, and crepey skin over time.
If you’re taking GLP-1 medications for weight loss like Ozempic, you may notice an acceleration in facial volume loss. The best solution is always preventative. But the effects of GLP-1 and GIP agonists on facial contours can appear as quickly as the weight disappears.
Why do GLP-1 and GIP agonists cause facial volume loss?
GLP-1 medications like Ozempic are highly effective for weight loss. However, they can also deplete skin’s supportive foundations. GLP-1 and GIP agonists are known to reduce production of collagen, elastin, and hyaluronic acid in the skin.
In addition to loss of fat and muscle, the loss of connective tissues can lead to visible changes in the appearance of the skin. Sadly, it can look a lot like accelerated skin aging, typical of more mature adults.
What facial changes can result from GLP-1 and GIP agonists?
These visible changes in your face can be confused with signs of advanced aging which begin to occur in your 50s and accelerate as you get older.
The visible effects of facial volume loss may include: sagging skin, particularly in the cheeks and jawline and hollowness around the eyes. The rapid loss of facial volume can cause a gaunt, aged appearance.
How can I fight the effects of facial changes due to GLP-1 medications?
To counter the effects of GLP-1 medications for weight loss, notably a loss of facial volume, you’ll need an approach which targets the appearance of facial skin in multiple dimensions.
IMAGE Skincare has introduced a targeted treatment Intentionally formulated by a plastic surgeon to address the specific skin concerns that occur with GLP-1 usage. This multi-dimensional formula works in 4D to improve the appearance of facial skin, including deflation, deep wrinkles, dehydration and density.
VOL.U.LIFT™: the first treatment for GLP-1 skin changes.
To treat loss of facial volume and other signs of “Ozempic Face,” IMAGE Skincare collaborated with Dr. Raja Sivamani, an Integrative Dermatologist and Adjunct Associate Professor of Dermatology at UC Davis.
Working in tandem with Dr. Sivamani, IMAGE Skincare co-founder and plastic surgeon Dr. Marc Ronert created a breakthrough solution: VOL.U.LIFT™ GLP-1 4D Skin Rebound Complex. It's the first and treatment developed for facial changes due to rapid weight loss when using GLP-1 agonists.
What does VOL.U.LIFT™ do to fight the effects of facial aging including GLP-1 skin changes?
VOL.U.LIFT™ GLP-1 4D Skin Rebound Complex is a revolutionary topical treatment that improves the appearance of facial skin in multiple dimensions: deflation, deep wrinkles, dehydration and density.
Going beyond traditional volumizing treatments, VOL.U.LIFT™ GLP-1 4D Skin Rebound Complex improves the appearance of deflation, sagging, crepey skin texture, dehydration, and wrinkles. The result? A visibly radiant, younger-looking complexion.
How does VOL.U.LIFT™ work to correct and prevent facial changes due to GLP-1 medications?
This multifaceted formula features patent-pending XOSM™ Technology plus a unique blend of ingredients intentionally selected for their unique properties that address the very specific facial changes that occur with GLP-1 use.
Our proprietary, XOSM™ Technology. Patent-pending XOSM™ Technology boosts formula performance while protecting and nourishing skin’s barrier with antioxidants, ectoin, vitamin C and astaxanthin-rich micro-algae.
VOL.U.LIFT™ performance is supercharged by HA Silanol, a next generation hyaluronic acid combined with silicium to improve hydration, plumping the skin to restore the appearance of volume.
In addition, a non-essential amino acid, L-ornithine, visibly plumps skin, improving the appearance of sunken, deflated skin and promoting a fuller, younger-looking face.
The combination of powerful actives specifically targets loss of facial volume to effectively address GLP-1 induced skin changes.
Your Privacy Choices